ArticleThe American journal of pathology2004
Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction.
Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 50 citations in OpenAlex.
- Long Non-Coding LEF1-AS1 Sponge miR-5100 Regulates Apoptosis and Autophagy in Gastric Cancer Cells via the miR-5100/DEK/AMPK-mTOR Axis.International journal of molecular sciences · 2022Article
- Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma.Cancers · 2021Review
- Role of the DEK oncogene in the development of squamous cell carcinoma.International journal of clinical oncology · 2020Review
- Dek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidence.PLoS genetics · 2018Article
- A role for intracellular and extracellular DEK in regulating hematopoiesis.Current opinion in hematology · 2017Review
- Article
- The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.Oncogene · 2015Article
- Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer.Journal of oncology · 2015Review
- DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2013Article
- Intercellular trafficking of the nuclear oncoprotein DEK.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.Cancer biology & therapy · 2012Article
- Article
- The human DEK oncogene regulates DNA damage response signaling and repair.Nucleic acids research · 2011Article
- DEK expression in melanocytic lesions.Human pathology · 2011Article
- The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.Oncogene · 2011Article
- Article
- DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.Arthritis and rheumatism · 2011Article
- Control of tumorigenesis and chemoresistance by the DEK oncogene.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Review
- Melanoma proliferation and chemoresistance controlled by the DEK oncogene.Cancer research · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metaphase-based comparative genomic hybridization (CGH) has identified recurrent regions of gain on different chromosomes in bladder cancer, including 6p22. These regions may contain activated oncogenes important in disease progression. Using quantitative multiplex polymerase chain reaction (QM-PCR) to study DNA from 59 bladder tumors, we precisely mapped the focal region of genomic gain on 6p22. The marker STS-X64229 had copy number increases in 38 of 59 (64%) tumors and the flanking markers, RH122450 and A009N14, had copy number gains in 33 of 59 (56%) and 26 of 59 (45%) respectively. Contiguous gain was present for all three markers in 14 of 59 (24%) and for two (RH122450 and STS-X64229) in 25 of 59 (42%). The genomic distance between the markers flanking STS-X64229 is 0.5 megabases, defining the minimal region of gain on 6p22. Locus-specific interphase fluorescence in situ hybridization confirmed the increased copy numbers detected by QM-PCR. Current human genomic mapping data indicates that an oncogene, DEK, is centrally placed within this minimal region. Our findings demonstrate the power of QM-PCR to narrow the regions identified by CGH to facilitate identifying specific candidate oncogenes. This also represents the first study identifying DNA copy number increases for DEK in bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.